Roivant Advances Brepocitinib Program, Refocuses Autoimmune Portfolio

Roivant Sciences ( (ROIV) ) has provided an update.

On April 2, 2026, Roivant announced that its subsidiary Priovant had launched a seamless Phase 2b/3 clinical program of brepocitinib in lichen planopilaris, a rare, highly morbid inflammatory scalp disorder with no FDA-approved therapies and an estimated 100,000 affected adults in the U.S. The new trial, which began enrolling patients in March 2026, extends brepocitinib’s late-stage footprint to a fourth indication, reinforcing Roivant’s strategy of building a multi-indication rare rheumatology and dermatology franchise alongside ongoing regulatory review in dermatomyositis and late-stage programs in non-infectious uveitis and cutaneous sarcoidosis.

In the same April 2, 2026 update, Roivant reported that Immunovant’s two Phase 3 studies of batoclimab in thyroid eye disease failed to meet their primary endpoint, although safety was consistent with prior data and greater proptosis improvement was observed during an initial high-dose period than in a subsequent low-dose phase. While the TED setback clouds the outlook for batoclimab, Roivant and Immunovant are emphasizing continued investment in next-generation FcRn blocker IMVT-1402—particularly in Graves’ disease—and plan to reassess batoclimab’s future with partner HanAll, a pivot that signals a strategic refocus within the company’s autoimmune portfolio.

The most recent analyst rating on (ROIV) stock is a Hold with a $29.00 price target. To see the full list of analyst forecasts on Roivant Sciences stock, see the ROIV Stock Forecast page.

Spark’s Take on ROIV Stock

According to Spark, TipRanks’ AI Analyst, ROIV is a Neutral.

ROIV scores as moderately attractive, led by strong pipeline/catalyst momentum (earnings call) and significant positive corporate events (Moderna settlement and FDA Priority Review), supported by favorable technical trend. The main constraint is weak financial performance driven by persistent losses and cash burn, with limited valuation support given the negative P/E and no dividend yield provided.

To see Spark’s full report on ROIV stock, click here.

More about Roivant Sciences

Roivant Sciences is a biopharmaceutical company that develops and commercializes medicines through a network of subsidiary “Vants,” focusing on autoimmune and rare diseases. Its pipeline includes brepocitinib, a JAK1/TYK2 inhibitor for multiple inflammatory indications, FcRn-targeting antibodies IMVT-1402 and batoclimab for IgG-mediated autoimmune conditions, and mosliciguat for pulmonary hypertension associated with interstitial lung disease.

The company aims to accelerate late-stage development in niche, high-unmet-need markets, particularly orphan rheumatology and dermatology indications, as well as broader autoimmune diseases. Beyond therapeutics, Roivant also incubates discovery-stage biotechs and health technology ventures that complement its core drug development activities, positioning it as a diversified player in the life sciences sector.

Average Trading Volume: 6,380,847

Technical Sentiment Signal: Buy

Current Market Cap: $19.93B

See more data about ROIV stock on TipRanks’ Stock Analysis page.